Company profile: 60 Degrees Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of medicines to treat and prevent infectious diseases, including ARAKODA (tafenoquine) for malaria prophylaxis in patients 18+, a Dengue Fever Treatment Program developing 60P001 (alpha-glucosidase inhibitor) and 60P002 (platelet-activating factor receptor antagonist), and a Malaria Prevention Program developing new drugs to address limitations of existing prophylactics.
Products and services
- ARAKODA (tafenoquine): Adult-indicated antimalarial drug used for malaria prophylaxis in patients aged 18 years and older, tafenoquine-based formulation engineered to prevent malaria infection
- Malaria Prevention Program: Development-stage program architected to create new antimalarial prophylactic drugs, addressing limitations of existing prophylactics through research on improved preventive pharmacology
- Dengue Fever Treatment Program: Mechanism-targeted program developing 60P001 (alpha-glucosidase inhibitor) and 60P002 (platelet-activating factor receptor antagonist) for the treatment of dengue fever, advancing dual agents with distinct receptor/enzyme targets
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to 60 Degrees Pharmaceuticals
MaxThera
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development of new treatments for bacterial infections, especially those caused by drug-resistant bacteria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MaxThera company profile →
Valneva
HQ: France
Website
- Description: Provider of prophylactic vaccines for infectious diseases, focusing on development and commercialization for unmet medical needs. Portfolio includes IXCHIQ (VLA1553), a live-attenuated, single-dose chikungunya vaccine approved in the U.S.; VLA15, a multivalent Lyme disease vaccine in Phase 3; and a tetravalent Shigella vaccine candidate developed with LimmaTech.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valneva company profile →
Binx Health
HQ: United States
Website
- Description: Provider of point-of-care and at-home diagnostic solutions, including binx io for chlamydia and gonorrhea testing with results in about thirty minutes; at-home STI sample collection kits available via digital health platforms; and at-home COVID-19 nasal swab sample collection kits for individual and bulk orders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Binx Health company profile →
Now Diagnostics
HQ: United States
Website
- Description: Provider of rapid, single-drop-of-blood diagnostic tests delivering results within minutes, including ADEXUSDx assays for COVID-19 antibodies, hCG for early pregnancy, syphilis antibodies, elevated acetaminophen, H-FABP for myocardial damage, and methanol detection in blood, plasma, or serum.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Now Diagnostics company profile →
Selux Diagnostics
HQ: United States
Website
- Description: Provider of next-generation phenotyping solutions for rapid antimicrobial susceptibility testing (AST). Offers the Selux NGP System, proprietary 384-well panels delivering exact MICs across a wide range of antibiotics, the Selux Separator and Inoculator for automated sample preparation from positive blood cultures, and Selux Site Software to streamline workflow and deliver actionable AST results.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Selux Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for 60 Degrees Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to 60 Degrees Pharmaceuticals
2.2 - Growth funds investing in similar companies to 60 Degrees Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for 60 Degrees Pharmaceuticals
4.2 - Public trading comparable groups for 60 Degrees Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →